01—Abstract
Summary
Summary of the 10-K filed February 25, 2020. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (Nasdaq: EXEL) is an oncology-focused biotechnology company whose 2019 results were driven by its flagship molecule cabozantinib, marketed as CABOMETYX (advanced renal cell carcinoma and previously treated hepatocellular carcinoma) and COMETRIQ (progressive, metastatic medullary thyroid cancer).
Net product revenues rose to $759.95 milliona in 2019 from $619.28 million in 2018, with CABOMETYX contributing $733.42 million. Total revenues were $967.78 million, up from $853.83 million, while collaboration revenues declined to $207.83 million from $234.55 million. Net income was $321.01 million, or $1.02 per diluted share, compared with $690.07 million in 2018, which had included a $244.1 million income tax benefit from the release of most of the valuation allowance on deferred tax assets.
Cash and investments totaled $1.39 billionb at year-end. The company expects 2020 net product revenues to remain in line with 2019 and collaboration revenues to decrease as fewer milestones are expected, while research and development and selling, general and administrative expenses are expected to keep increasing. Research and development expenses rose to $336.96 million from $182.26 million, driven by clinical trial costs and collaboration costs.
Key pipeline items include COSMIC-311 (differentiated thyroid cancer), COSMIC-313 and COSMIC-312 phase 3 trials, and XL092, a next-generation oral TKI in phase 1. The filing also discloses a Paragraph IV patent challenge from MSN Pharmaceuticals over a generic CABOMETYX tablet, with Exelixis suing in October 2019; a bench trial is tentatively scheduled for April 2022. Investors should note the concentration of revenue in cabozantinib, reliance on partners Ipsen and Takeda for ex-U.S. commercialization, the generic litigation risk tied to the composition-of-matter patent expiring in 2026, and the lumpy nature of milestone revenue, which was $96.2 millionc in 2019 versus $164.4 million in 2018.
02—Key points
Key Highlights
- Total revenues rose to $967.78 million in 2019 from $853.83 million in 2018, while net product revenues grew to $759.95 million from $619.28 million.
- CABOMETYX net product revenues were $733.42 million in 2019 versus $599.95 million in 2018; COMETRIQ contributed $26.53 million.
- Net income was $321.01 million ($1.02 per diluted share) in 2019, down from $690.07 million in 2018, which included a $244.1 million tax benefit.
- Research and development expenses increased to $336.96 million from $182.26 million, and the company expects R&D and SG&A expenses to keep rising in 2020.
- Cash and investments reached $1.39 billion at December 31, 2019, up from $851.6 million a year earlier.
- Management expects 2020 net product revenues to remain in line with 2019 and collaboration revenues to decrease due to fewer expected milestones.
- MSN Pharmaceuticals filed an ANDA for a generic CABOMETYX tablet; Exelixis sued in October 2019, with a bench trial tentatively scheduled for April 2022.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2020, Exelixis kept $0.33.
- Revenue$967.8M100.0%
- Cost of revenue−$33.1M3.4%
- Gross profit$934.7M96.6%
- Operating costs−$565.2M58.4%
- Operating income$369.5M38.2%
- Interest, other & tax−$48.5M5.0%
- Net income$321.0M33.2%
Where FY2020 revenue went
$967.8M- R&D: $337.0M, 35% of revenue
- Net income: $321.0M, 33% of revenue
- SG&A: $228.2M, 24% of revenue
- Cost of revenue: $33.1M, 3.4% of revenue
- Interest, other & tax: $48.5M, 5.0% of revenue
Kept 33% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 25, 2020Financial Statements
| Revenue | $967.77M |
| Cost of Revenue | $33.10M |
| Gross Profit | $934.68M |
| R&D Expenses | $336.96M |
| SG&A Expenses | $228.24M |
| Operating Expenses | $598.30M |
| Operating Income | $369.47M |
| Interest Expense | $0 |
| Net Income | $321.01M |
| EPS (Basic) | $1.06 |
| EPS (Diluted) | $1.02 |
| Shares Outstanding (Basic) | 302.58M |
| Shares Outstanding (Diluted) | 315.01M |
05—Questions
Frequently Asked Questions
How much of Exelixis's revenue depends on CABOMETYX?
Net product revenues of $733.42 million from CABOMETYX made up most of the $759.95 million in 2019 net product revenues. Ipsen accounted for 16% of total 2019 revenues, and CVS Health affiliates for 15%, with ex-U.S. CABOMETYX sales driving royalties to Exelixis.
Why did net income fall in 2019 despite higher revenues?
2018 net income of $690.07 million included a $244.1 million income tax benefit from releasing most of the valuation allowance on deferred tax assets. In 2019, the company recorded a $77.10 million income tax provision, and operating expenses rose to $598.31 million from $414.97 million.
What is the main patent risk for CABOMETYX?
MSN Pharmaceuticals filed an ANDA with a Paragraph IV certification against U.S. Patent No. 8,877,776, and Exelixis filed a patent infringement complaint in October 2019. The composition-of-matter patent ('473 Patent) is listed to expire in 2026, and the filing notes that a generic version could significantly reduce revenue if approved.
What are the key clinical catalysts mentioned in the filing?
The filing cites COSMIC-311 in differentiated thyroid cancer, with the first 100 patients enrolled in February 2020 and an interim PFS analysis expected in the second half of 2020. It also cites BMS's CheckMate 9ER top-line results expected in the first half of 2020, and COSMIC-313 top-line results expected in the 2022 timeframe.
06—Continue